Resverlogix Corp. Net Assets
Resverlogix Corp. net assets. Based on the latest financial reports, Resverlogix Corp. (RVX) has net assets worth CA$-94.12 Million CAD (≈ $-68.08 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$8.24 Million ≈ $5.96 Million USD) and total liabilities (CA$102.36 Million ≈ $74.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Resverlogix Corp. to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-94.12 Million |
| % of Total Assets | -1141.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 394.84 |
Net Assets of Resverlogix Corp. (2001–2025)
Net assets of Resverlogix Corp. from 2001 to 2025. This chart illustrates how Resverlogix Corp.'s net assets have evolved over time, based on quarterly financial data. See Resverlogix Corp. (RVX) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Resverlogix Corp. (2001–2025)
The table below shows the annual net assets of Resverlogix Corp. from 2001 to 2025. For live market cap and overall valuation, see how much is Resverlogix Corp. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CA$-88.80 Million ≈ $-64.24 Million |
-8.64% |
| 2024-12-31 | CA$-81.73 Million ≈ $-59.13 Million |
-9.75% |
| 2023-12-31 | CA$-74.47 Million ≈ $-53.87 Million |
-25.63% |
| 2022-12-31 | CA$-59.28 Million ≈ $-42.88 Million |
+0.98% |
| 2021-12-31 | CA$-59.87 Million ≈ $-43.31 Million |
-50.07% |
| 2020-12-31 | CA$-39.90 Million ≈ $-28.86 Million |
+37.77% |
| 2019-12-31 | CA$-64.11 Million ≈ $-46.38 Million |
+69.14% |
| 2018-12-31 | CA$-207.72 Million ≈ $-150.26 Million |
-148.24% |
| 2017-12-31 | CA$-83.68 Million ≈ $-60.53 Million |
+17.62% |
| 2016-12-31 | CA$-101.57 Million ≈ $-73.47 Million |
-79.99% |
| 2015-12-31 | CA$-56.43 Million ≈ $-40.82 Million |
+23.46% |
| 2014-12-31 | CA$-73.73 Million ≈ $-53.33 Million |
-16.63% |
| 2013-12-31 | CA$-63.22 Million ≈ $-45.73 Million |
-114.26% |
| 2012-12-31 | CA$-29.50 Million ≈ $-21.34 Million |
-1176.40% |
| 2011-12-31 | CA$2.74 Million ≈ $1.98 Million |
-36.25% |
| 2010-12-31 | CA$4.30 Million ≈ $3.11 Million |
-3.67% |
| 2009-12-31 | CA$4.46 Million ≈ $3.23 Million |
-61.55% |
| 2008-12-31 | CA$11.61 Million ≈ $8.40 Million |
+113.35% |
| 2007-12-31 | CA$5.44 Million ≈ $3.94 Million |
+633.01% |
| 2006-12-31 | CA$-1.02 Million ≈ $-738.42K |
-113.64% |
| 2005-12-31 | CA$7.48 Million ≈ $5.41 Million |
-24.01% |
| 2004-12-31 | CA$9.84 Million ≈ $7.12 Million |
+279.07% |
| 2003-12-31 | CA$2.60 Million ≈ $1.88 Million |
+175.63% |
| 2002-12-31 | CA$942.21K ≈ $681.58K |
+262.89% |
| 2001-12-31 | CA$259.64K ≈ $187.82K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Resverlogix Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47691667737.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Resverlogix Corp. Net Assets Breakdown (December 2025)
Resverlogix Corp. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$334.32 Million | % |
| Other Components | CA$53.84 Million | % |
| Total Equity | CA$-88.80 Million | 100.00% |
Resverlogix Corp. Competitors by Market Cap
The table below lists competitors of Resverlogix Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ADS Maritime Holding Plc
OL:ADS
|
$18.68 Million |
|
YX Precious Metals Bhd
KLSE:0250
|
$18.69 Million |
|
Mexco Energy Corporation
NYSE MKT:MXC
|
$18.69 Million |
|
Shivam Autotech Limited
NSE:SHIVAMAUTO
|
$18.70 Million |
|
Tandy Leather Factory Inc
NASDAQ:TLF
|
$18.68 Million |
|
Aciselsan Acipayam Seluloz Sanayi Ve Ticaret AS
IS:ACSEL
|
$18.67 Million |
|
Daelim Trading
KO:006570
|
$18.66 Million |
|
Lodzia
TA:LODZ
|
$18.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Resverlogix Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -81,735,000 to -88,800,102, a change of -7,065,102.
- Net loss of 7,902,965 reduced equity.
- Other factors increased equity by 837,863.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-7.90 Million | -8.9% |
| Other Changes | CA$837.86K | +0.94% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Resverlogix Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CA$0.08 | CA$0.08 | x |
| 2002-12-31 | CA$0.09 | CA$0.08 | x |
| 2003-12-31 | CA$0.16 | CA$0.08 | x |
| 2004-12-31 | CA$0.48 | CA$0.08 | x |
| 2005-12-31 | CA$0.31 | CA$0.08 | x |
| 2006-12-31 | CA$-0.04 | CA$0.08 | x |
| 2007-12-31 | CA$0.21 | CA$0.08 | x |
| 2008-12-31 | CA$0.39 | CA$0.08 | x |
| 2009-12-31 | CA$0.11 | CA$0.08 | x |
| 2010-12-31 | CA$0.08 | CA$0.08 | x |
| 2011-12-31 | CA$0.04 | CA$0.08 | x |
| 2012-12-31 | CA$-0.40 | CA$0.08 | x |
| 2013-12-31 | CA$-0.80 | CA$0.08 | x |
| 2014-12-31 | CA$-0.87 | CA$0.08 | x |
| 2015-12-31 | CA$-0.56 | CA$0.08 | x |
| 2016-12-31 | CA$-0.96 | CA$0.08 | x |
| 2017-12-31 | CA$-0.61 | CA$0.08 | x |
| 2018-12-31 | CA$-1.02 | CA$0.08 | x |
| 2019-12-31 | CA$-0.29 | CA$0.08 | x |
| 2020-12-31 | CA$-0.17 | CA$0.08 | x |
| 2021-12-31 | CA$-0.25 | CA$0.08 | x |
| 2022-12-31 | CA$-0.23 | CA$0.08 | x |
| 2023-12-31 | CA$-0.28 | CA$0.08 | x |
| 2024-12-31 | CA$-0.30 | CA$0.08 | x |
| 2025-12-31 | CA$-0.31 | CA$0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Resverlogix Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-109.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -15.09% | -663.84% | 0.02x | 1.14x | CA$-65.14K |
| 2002 | -54.43% | 0.00% | 0.00x | 1.15x | CA$-607.05K |
| 2003 | -54.33% | -8020.21% | 0.01x | 1.04x | CA$-1.67 Million |
| 2004 | -28.82% | -1620.79% | 0.02x | 1.04x | CA$-3.82 Million |
| 2005 | -85.33% | -2620.11% | 0.03x | 1.08x | CA$-7.13 Million |
| 2006 | 0.00% | -5707.10% | 0.02x | 0.00x | CA$-16.45 Million |
| 2007 | -516.95% | 0.00% | 0.00x | 3.81x | CA$-28.67 Million |
| 2008 | -155.95% | -13101.81% | 0.01x | 1.63x | CA$-19.26 Million |
| 2009 | -615.35% | -979685.04% | 0.00x | 1.89x | CA$-27.91 Million |
| 2010 | -514.48% | -26691.77% | 0.01x | 1.96x | CA$-22.55 Million |
| 2011 | -685.22% | 0.00% | 0.00x | 4.51x | CA$-19.06 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | CA$46.31 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-48.78 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | CA$25.70 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-14.07 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-36.05 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-49.94 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | CA$20.61 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | CA$124.44 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | CA$3.99 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-18.78 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | CA$2.32 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-9.29 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | CA$538.50K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | CA$977.05K |
Industry Comparison
This section compares Resverlogix Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $15,150,773
- Average return on equity (ROE) among peers: -5.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Resverlogix Corp. (RVX) | CA$-94.12 Million | -15.09% | N/A | $18.68 Million |
| Appili Therapeutics Inc (APLI) | $-10.92 Million | 0.00% | 0.00x | $464.29K |
| Aptose Biosciences Inc (APS) | $118.92 Million | -46.45% | 0.06x | $4.43 Million |
| Arch Biopartners Inc (ARCH) | $-3.88 Million | 0.00% | 0.00x | $43.24 Million |
| Biomind Labs Inc (BMND) | $-1.43 Million | 0.00% | 0.00x | $19.92 Million |
| Cybin Inc (CYBN) | $1.45 Million | 0.00% | 0.18x | $301.37 Million |
| Eastwood Bio-Medical Canada Inc (EBM) | $1.31 Million | -44.19% | 0.26x | $89.55 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $45.77 Million | -76.33% | 0.10x | $353.56 Million |
| Devonian Health Group Inc (GSD) | $5.19 Million | 111.16% | 1.26x | $12.57 Million |
| Helix BioPharma Corp. (HBP) | $-844.00K | 0.00% | 0.00x | $50.83 Million |
| Hemostemix Inc (HEM) | $-4.05 Million | 0.00% | 0.00x | $6.82 Million |
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more